TALVEY field medical readthrough
Audio ReadthroughRead as writtenVersion 1· AI-generated · Internal use · Oct 4, 09:12
Page 4. Evidence update.
Updated data from the pivotal study show an overall response rate of 74% in the weekly dosing cohort.
Visual description
Table: response rates by dosing cohort, weekly 74%, biweekly 71%.
Page 9. Patient selection.
The update describes patients with relapsed or refractory multiple myeloma who received at least four prior lines of therapy.
Page 15. Field discussion guidance.
Field medical colleagues should respond to unsolicited questions only and use the approved slide set.
Page 22. Important safety information.
Protected
Cytokine release syndrome and neurologic toxicity, including ICANS, can occur. Refer to the full prescribing information.
Evidence update
Sam · Narrator